Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05BQK
|
|||
| Former ID |
DAP000668
|
|||
| Drug Name |
Butalbital
|
|||
| Synonyms |
Alisobumal; Alisobumalum; Allylbarbital; Allylbarbitone; Allylisobutylbarbital; Allylisobutylbarbiturate; Butalbarbital;Butalbitale; Butalbitalum; Itobarbital; Profundal; Sandoptal; Tetrallobarbital; Butalbitale [DCIT]; Axocet (TN); Axotal (TN); Bucet (TN); Bupap (TN); Butalbital [USAN:INN]; Butalbitalum [INN-Latin]; Cephadyn (TN); Dolgic (TN); Esgic (TN); Fioricet (TN); Fiorinal (TN); Fiormor (TN); Fiortal (TN); Fortabs (TN); IBS-L0126512; Iso-butylallylbarbituric acid; Laniroif (TN); Phrenilin (TN); Phrenilin Forte (TN); Sandoptal (TN); Sedapap (TN); Butalbital (USP/INN); Esgic-Plus (TN); 5-(2-methylpropyl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione; 5-Allyl-5-(2'-methyl-n-propyl) barbituric acid; 5-Allyl-5-(2-methylpropyl)barbituric acid; 5-Allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione; 5-Allyl-5-isobutylbarbituric acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anxiety disorder [ICD-11: 6B00-6B0Z] | Approved | [1], [2], [3] | |
| Headache [ICD-11: 8A80-8A84] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Analgesics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H16N2O3
|
|||
| Canonical SMILES |
CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C
|
|||
| InChI |
1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
|
|||
| InChIKey |
UZVHFVZFNXBMQJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 77-26-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5615386, 8150125, 8151657, 10535514, 11336145, 11361384, 11462356, 15018886, 17397336, 29221645, 46505876, 47589070, 48415671, 49873698, 50842826, 57321346, 71821583, 85308112, 99302058, 103166017, 104300716, 107945884, 117367338, 119511319, 126678058, 129444403, 134337957, 134972311, 135366363, 137131388, 137192290, 138744648, 152033795, 160963589, 164837438, 165745221, 175266092, 175611865, 177749228, 178103714, 179116585, 198993186, 223681171, 226458906, 241142339, 250049255
|
|||
| ChEBI ID |
CHEBI:102524
|
|||
| SuperDrug ATC ID |
N05CA07
|
|||
| SuperDrug CAS ID |
cas=000115446
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA(A) receptor alpha-1 (GABRA1) | Target Info | Antagonist | [4] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Retrograde endocannabinoid signaling | ||||
| GABAergic synapse | ||||
| Morphine addiction | ||||
| Nicotine addiction | ||||
| Reactome | Ligand-gated ion channel transport | |||
| GABA A receptor activation | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| Iron uptake and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7138). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076528. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.